Presence of Extra-Hepatic Disease Should Not Preclude Transarterial Chemoembolization for Metastatic Carcinoid

Arrese David, Feria-Arias Enrique, Hatzaras Ioannis, Guy Gregory, Khabiri Hooman, Schmidt Carl, Shah Manisha, Bloomston Mark

The Ohio State University Medical Center; 410 W 10th Ave N924 Doan, Columbus, OH 43210

Background: Transarterial chemoembolization (TACE) is the locoregional therapy of choice for the management of patients with inoperable carcinoid liver metastases. Often, metastatic disease is not limited to the liver. The impact of extra-hepatic metastases on response and outcomes following TACE has not been described.

Objective: We hypothesized that patients who, at the time of TACE, have extra-hepatic disease would have similar tumor response and symptom control following TACE.

Methods: We reviewed 198 patients that underwent TACE for incurable carcinoid liver metastases. Two groups were identified, those with (N= 129) and without (N= 69) evidence of extra-hepatic disease at the time of TACE. Demographics, clinicopathologic characteristics, response to TACE, complications, and survival were compared.

Results: The two groups were similar in demographics and histopathologic characteristics. Complications following TACE were similar. There was no difference between the groups with and without evidence of extrahepatic disease in symptomatic (76% vs 71%), biochemical (78% vs 90%) or radiographic response (35.0% vs 46%) to TACE. The group without extra-hepatic disease had a median survival of 88 vs 35 months with five-year survival of 65% vs 30% compared to patients with extra-hepatic disease at the time of TACE.

Conclusion: As expected, patients with extrahepatic metastatic disease from carcinoid tumor experienced shorter overall survival following TACE compared to those without extrahepatic disease. However, patients with extra-hepatic disease had similar symptomatic, biochemical and radiographic response to TACE compared to those with disease confined to the liver. Although the
long-term prognosis for patients with extrahepatic disease is worse than those with liver-only metastasis, meaningful response to TACE is possible and should be considered in those with carcinoid syndrome.